Phreesia president David Linetsky buys $682 in company stock
What it means
- What to watch: David Linetsky's $682 purchase is a small bet, but it's the kind of move that can signal confidence or just a personal whim — keep an eye on the trend around it.
- How the stock is trading: $PHR -0.71% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$PHR last traded at $12.61, -0.71% on the session. That puts it 47% shy of its 52-week high of $23.87 and 62% clear of its low of $7.77 — a little below the middle of the range. Over the year it has ranged 207% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $PHR page.
How much coverage it is getting
Nothing else on $PHR in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, news cycles are driven by trials, FDA rulings, and pricing shifts. A single drugmaker can swing, but a policy change can shake the whole sector. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$PHR earnings in 48 days. These were on the calendar before this story and are not caused by it.
What to watch next
The $PHR page has the full chart, filings, and valuation model. Compare one outlet to another to see if the story is confirmed or just repeated. Wook AI can pull live data and run the numbers on request.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $PHR. It carried $682, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.